David Mark Slager Net Worth

The estimated Net Worth of David Mark Slager is at least $3.13 Milion dollars as of 31 October 2017. David Slager owns over 16,892 units of Oramed Pharmaceuticals, Inc stock worth over $3,132,861 and over the last 8 years David sold ORMP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Slager ORMP stock SEC Form 4 insiders trading

David has made over 2 trades of the Oramed Pharmaceuticals, Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently David exercised 16,892 units of ORMP stock worth $63,683 on 31 October 2017.

The largest trade David's ever made was exercising 112,613 units of Oramed Pharmaceuticals, Inc stock on 17 August 2017 worth over $424,551. On average, David trades about 25,901 units every 15 days since 2017. As of 31 October 2017 David still owns at least 1,316,328 units of Oramed Pharmaceuticals, Inc stock.

You can see the complete history of David Slager stock trades at the bottom of the page.

What's David Slager's mailing address?

David's mailing address filed with the SEC is 152 WEST 57TH STREET,, 9TH FLOOR, NEW YORK, NY, 10019.

Insiders trading at Oramed Pharmaceuticals, Inc

Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank oraz Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.

What does Oramed Pharmaceuticals, Inc do?

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg

Complete history of David Slager stock trades at Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals, Inc executives and stock owners

Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:

• Nadav Kidron,
  President, Chief Executive Officer, Director
• Nadav Kidron Esq.,
  Pres, CEO & Exec. Director
• Miriam Kidron,
  Chief Scientific Officer, Director
• Joshua Hexter,
  Chief Operating and Business Officer
• Dr. Miriam Kidron Ph.D.,
  Chief Scientific Officer & Director
• Dr. Miriam Kidron,
  Chief Scientific Officer & Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Joshua Hexter,
  Chief Operating & Bus. Officer
• David Silberman,
  CFO, Treasurer & Sec.
• Avraham Gabay,
  Chief Financial Officer, Treasurer, Secretary
• Kevin Rakin,
  Independent Chairman of the Board
• Leonard Sank,
  Independent Director
• Arie Mayer,
  Independent Director
• Xiaoming Gao,
  Independent Director
• Aviad Friedman,
  Independent Director
• Dr. Roy Eldor M.D., Ph.D.,
  Chief Medical Advisor & Member of the Scientific Advisory Board
• Daniel Aghion,
  Director
• Capital Management Lp Regal...,
  
• Xiaopeng Li,
  Director
• David Mark Slager,
  Director
• Harold Jacob,
  Director
• Gerald M Ostrov,
  Director
• Capital Management Lp Regals,
  10% owner
• Ronald Edward Law,
  Chief Strategy Officer
• Michael Berelowitz,
  Director
• Yifat Hen Zommer,
  CFO, Treasurer and Secretary
• Hilla Eisenberg,
  CFO, Treasurer and Secretary
• David Silberman,
  Chief Financial Officer
• Mark Daniel Hasleton,
  VP Business Development
• Michael Rabinowitz,
  Chief Commercial Officer
• Chaime Orlev,
  CFO, TREASURER AND SECRETARY
• Benjamin Shapiro,
  Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Netanel Derovan,
  Chief Legal Officer
• Yadin Rozov,
  Director
• Yehuda Reznick,
  Director